Sinovac Biotech Ltd

Find Ratings Reports
SVA : NASDAQ : Health Care
$5.85 -0.03 | -0.51%
Today's Range: 5.82 - 5.89
Avg. Daily Volume: 93,600
07/28/16 - 3:58 PM ET

Financial Analysis


SINOVAC BIOTECH LTD's gross profit margin for the first quarter of its fiscal year 2016 has decreased when compared to the same period a year ago. The company has grown sales and net income during the past quarter when compared with the same quarter a year ago, however, it was unable to keep up with the growth of the average competitor within its industry. SINOVAC BIOTECH LTD has strong liquidity. Currently, the Quick Ratio is 1.79 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 1.05% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)10.959.21
EBITDA ($mil)-0.69-0.33
EBIT ($mil)-2.19-2.01
Net Income ($mil)1.31-2.25


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)64.1563.07
Total Assets ($mil)204.51212.46
Total Debt ($mil)35.9533.14
Equity ($mil)123.43124.75


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin71.593.24
EBITDA Margin-6.26-3.56
Operating Margin-19.99-21.87
Sales Turnover0.340.28
Return on Assets1.21-1.46
Return on Equity0.7-2.33
Debt Q1 FY16 Q1 FY15
Current Ratio2.22.2
Debt/Capital0.230.21
Interest Expense0.380.59
Interest Coverage-5.72-3.43


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)56.9156.0
Div / share0.00.0
EPS-0.02-0.04
Book value / share2.172.23
Institutional Own % n/a n/a
Avg Daily Volume91180.0137080.0

Valuation


HOLD. SINOVAC BIOTECH LTD's P/E ratio indicates a significant premium compared to an average of 40.39 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 25.05. To use another comparison, its price-to-book ratio of 2.74 indicates valuation on par with the S&P 500 average of 2.81 and a significant discount versus the industry average of 11.16. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
SVA 595.00 Peers 40.39   SVA 233.70 Peers 21.72

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

SVA is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

SVA is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
SVA NA Peers 122.62   SVA NA Peers 1.15

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
SVA 2.74 Peers 11.16   SVA 116.66 Peers -19.12

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

SVA is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

SVA is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
SVA 4.90 Peers 425.82   SVA 17.59 Peers 40.81

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

SVA is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

SVA significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades